Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.
External link for Neuspera Medical Inc.
San Jose, US
Neuspera Medical Inc. reposted this
A new chapter for urinary urge incontinence (UUI) treatment begins. The FDA has approved Neuspera’s integrated sacral neuromodulation (iSNM) system, a smart, patient-centered alternative to traditional SNM therapies. Our iSNM system delivers proven UUI treatment to improve quality of life for the 1 in 5 U.S. women impacted by overactive bladder, often resulting in UUI. #Neuspera #UUI #MedicalInnovation #FDAApproval
A new chapter for urinary urge incontinence (UUI) treatment begins. The FDA has approved Neuspera’s integrated sacral neuromodulation (iSNM) system, a smart, patient-centered alternative to traditional SNM therapies. Our iSNM system delivers proven UUI treatment to improve quality of life for the 1 in 5 U.S. women impacted by overactive bladder, often resulting in UUI. #Neuspera #UUI #MedicalInnovation #FDAApproval
What if treating urinary incontinence didn’t require a bulky battery implant? That’s the future we’re enabling at Neuspera. We had an incredible few days connecting with urologists from around the world at American Urological Association (AUA) 2025 Annual Conference. The excitement around our ultra-miniaturized, battery-free percutaneous sacral neuromodulation (pSNM) system was energizing. Designed to relieve urgency urinary incontinence (UUI) without the burden of a battery implant, Neuspera is leading the development of wireless, directionally adaptive energy systems to power tiny medical implants deep within the body — and this is just the beginning. Investigational use only. #AUA2025 #BioelectronicMedicine #Neuspera #MedicalInnovation #UUI #Urology Steve Paul, Mark Vollmer, Alexander Yeh, Zygmunt Porada, Steven Siegel, Tom Bombeck
A smaller device. A bigger conversation. The Neuspera team showcased the first wireless, battery-free, ultra-miniaturized percutaneous sacral neuromodulation (pSNM) device for urgency urinary incontinence (UUI) at the American Urological Association (AUA) 2025 Annual Conference in Las Vegas — the largest gathering of urologists in the world. Our poster session sparked incredible engagement and important conversations about the future of bioelectronic medicine. Thank you to everyone who stopped by. See you next year! Investigational use only. #AUA2025 #BioelectronicMedicine #Neuspera #MedicalInnovation #UUI #Urology Steve Paul, Mark Vollmer, Alexander Yeh, Zygmunt Porada, Steven Siegel, Tom Bombeck
We’re excited to welcome Steve Paul as Chief Commercial Officer at Neuspera! Steve brings deep experience scaling commercial organizations and a strong track record of launching category-defining medical technologies. He joins Neuspera at a pivotal time as we prepare to bring our initial innovation to market: the first wireless, battery-free, ultra-miniaturized percutaneous sacral neuromodulation (pSNM) device for urgency urinary incontinence (UUI), currently pending FDA approval. Steve will lead our commercial strategy and team-building efforts as we move toward launch and expand access to this much-needed solution. Join us in welcoming Steve to the team as we continue advancing the future of bioelectronic medicine. For Investigational Use Only. #Neuspera #pSNM #UUI #MedTech #BioelectronicMedicine
Neuspera’s six-month pivotal trial data shows that our battery-free percutaneous sacral neuromodulation (pSNM) system has similar effectiveness rates as traditional sacral neuromodulation (SNM) devices — while aiming to provide a significantly better patient experience for urgency urinary incontinence (UUI). Note: Neuspera’s device is for Investigational Use Only. 🔗 Learn more here: https://lnkd.in/g6HhHinu #Urology #UUI #MedTech #ClinicalTrial
Neuspera Medical is delighted to announce that the primary endpoint results of our Pivotal Phase II SANS UUI clinical study have been accepted for podium presentation during SUFU’s annual winter meeting, February 26 – March 1, 2025, in Rancho Mirage, California. Our SANS-UUI National PI, Dr. Osvaldo Padron will present “TREATMENT OF OAB SYMPTOMS USING NEUSPERA’S ULTRA-MINIATURIZED SYSTEM: 6-MONTH RESULTS OF THE SANS-UUI PHASE II STUDY” at 8:00AM during the OAB/Chemodenervation Podium Session, 7:30-9:00AM on Saturday, March 1st. The full SUFU program schedule can be viewed online. https://lnkd.in/gqsTBTw3 We hope to see you there! #SUFU #OAB #Urology